# Xeris Biopharma Holdings Inc. (XERS) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $10.35, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Xeris Biopharma Holdings Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.53**. A PEG of 0.53 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 5.6×**. Each dollar of revenue is priced at 5.6×.
- **EV / EBITDA: 52.6×**. Enterprise value is 52.6× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.

## Profitability
- **Operating margin: 10.9%**. 10.9% of revenue is left after running the business.
- **Net margin: 0.2%**. 0.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 4.0%**. 4.0% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 23.5%**. Return on all capital, debt included, is 23.5%: comfortably above what that capital costs.
- **Return on assets: -4.5%**. Each dollar of assets produces -4.5% of profit.

## Growth
- **Revenue growth (1 yr): 43.7%** (3-yr 38.3%/yr, 5-yr 70.7%/yr). Revenue grew 43.7% over the last year, against 70.7% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 100.0%**. Earnings per share rose 100.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 16.10**. Debt is 16.10 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 2.9×**. It would take 2.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.19** (quick 2.19). Current assets cover the next year's liabilities 2.19 times.
- **Altman Z-score: 4.50**. A Z-score of 4.50 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Xeris Biopharma Holdings Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 4.8%** (YTD 29.6%, 3-mo 25.1%). The shares are up 4.8% over twelve months including dividends.
- **From 52-week high: -9.4%** (97.1% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 0.88** (volatility 54%). Beta of 0.88 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=XERS · Page: https://foliofundamentals.com/stocks/xers

Not investment advice.